![]() | |
Clinical data | |
---|---|
Other names | Progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt; Pregn-4-ene-3,20-dione 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt |
Drug class | Neurosteroid |
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C22H32NNa2O6P |
Molar mass | 483.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
EIDD-1723, also known as EPRX-01723 or as progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt, is a synthetic, water-soluble analogue of progesterone and a neurosteroid which was developed for the potential treatment of traumatic brain injury. [1] [2] It is a rapidly converted prodrug of EIDD-036 (EPRX-036; progesterone 20-oxime), which is considered to be the active form of the agent. [1] Previous C3 and C20 oxime derivatives of progesterone, such as P1-185 (progesterone 3-O-(L-valine)-E-oxime), were also developed and studied prior to EIDD-1723. [3] [4]
![]() | |
Clinical data | |
---|---|
Other names | Progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt; Pregn-4-ene-3,20-dione 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt |
Drug class | Neurosteroid |
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C22H32NNa2O6P |
Molar mass | 483.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
EIDD-1723, also known as EPRX-01723 or as progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt, is a synthetic, water-soluble analogue of progesterone and a neurosteroid which was developed for the potential treatment of traumatic brain injury. [1] [2] It is a rapidly converted prodrug of EIDD-036 (EPRX-036; progesterone 20-oxime), which is considered to be the active form of the agent. [1] Previous C3 and C20 oxime derivatives of progesterone, such as P1-185 (progesterone 3-O-(L-valine)-E-oxime), were also developed and studied prior to EIDD-1723. [3] [4]